Loading patent…
AssigneeYale University
InventorsAnthony N. Van Den Pol, Guido Wollmann
Estimating the term…
Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.
A method of treating cancer comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric Vesicular stomatitis virus (VSV) to treat the cancer, wherein the chimeric VSV's genome comprises nucleic acid sequences encoding a VSV nucleoprotein (N), VSV phosphoprotein (P), VSV matrix (M) protein, VSV large (L) viral polymerase, and a heterologous glycoprotein derived from Ebola virus or Lassa virus comprising an amino acid sequence with at least 80% sequence identity to one of SEQ ID NOS:
A method of treating cancer comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric Vesicular stomatitis virus (VSV) to treat the cancer, wherein the chimeric VSV's genome comprises nucleic acid sequences encoding a VSV nucleoprotein (N), VSV phosphoprotein (P), VSV matrix (M) protein, VSV large (L) viral polymerase, and a heterologous glycoprotein derived from Lassa virus comprising an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2, and lacks a nucleic acid sequence encoding VSV glycoprotein (G).
A method of treating cancer comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric Vesicular stomatitis virus (VSV) to treat the cancer, wherein the chimeric VSV's genome comprises nucleic acid sequences encoding a VSV nucleoprotein (N), VSV phosphoprotein (P), VSV matrix (M) protein, VSV large (L) viral polymerase, and a heterologous glycoprotein derived from Ebola virus comprising an amino acid sequence with at least 90% sequence identity to SEQ ID NO:7 with or without the mucin domain, and lacks a nucleic acid sequence encoding VSV glycoprotein (G).
Dependencies are inferred from the claim text.